22
Jul
In response to a letter regarding representation by a Member of Parliament, Mr Anurag Khera (Sr. Vice-president-Corporate Affairs) of Glenmark pharmaceuticals Limited sent a letter to Dr VG Somani, Director General of Health Services, Central Drugs Standard Control Organisation, clarifying its stand on the product Favipiravir tablets (200mg) manufactured and marketed by Glenmark that was granted permission by the latter’s office. Glenmark said, compared to other therapies approved for emergency use in COVID-19, Favipiravir (FabiFlu) is much more economical and an effective treatment option. The estimated total cost of therapy for full course with Favipiravir is Rs 9150, while Remdesivir,…